论文部分内容阅读
目的:探讨ERα-36在乳腺浸润性导管癌的表达及相关因素。方法:应用免疫组织化学法检测70例乳腺浸润性导管癌组织中ERα-36的表达,比较ERα-36在4种分子亚型中的表达,及其与年龄、肿瘤大小、临床分期、组织学分级、淋巴结转移、ERα-66、PR、Her-2、Ki-67的关系。结果:ERα-36在浸润性导管癌组织的阳性率为52.9%,在luminal A型、luminal B型、Her-2过表达型、三阴性乳腺癌中的阳性率分别为40.9%、30.1%、66.7%、84.6%;ERα-36在三阴性及非三阴性乳腺癌的阳性率分别为84.6%和45.6%,有统计学差异(P<0.05)。ERα-36表达与ERα-66、Ki-67及淋巴结转移有关(P<0.05),而与年龄、肿瘤大小、临床分期、组织学分级、PR、Her-2无关(P>0.05)。结论:ERα-36在三阴性乳腺癌中高表达,提示其可作为三阴性乳腺癌治疗的潜在靶点。
Objective: To investigate the expression of ERα-36 in breast invasive ductal carcinoma and its related factors. Methods: The expression of ERα-36 in 70 cases of breast invasive ductal carcinoma was detected by immunohistochemistry. The expression of ERα-36 in 4 subtypes was compared with age, tumor size, clinical stage, histological score Grade, lymph node metastasis, ERα-66, PR, Her-2, Ki-67. Results: The positive rate of ERα-36 in invasive ductal carcinoma was 52.9%. The positive rates of ERα-36 in luminal A, luminal B, Her-2 overexpression and triple negative breast cancer were 40.9%, 30.1% 66.7% and 84.6%, respectively. The positive rates of ERα-36 in triple-negative and non-triple-negative breast cancer were 84.6% and 45.6% respectively, with statistical significance (P <0.05). The expression of ERα-36 was correlated with ERα-66, Ki-67 and lymph node metastasis (P <0.05), but not with age, tumor size, clinical stage, histological grade, PR and Her-2. Conclusion: The overexpression of ERα-36 in triple-negative breast cancer suggests that it may serve as a potential target for the treatment of triple negative breast cancer.